83 related articles for article (PubMed ID: 21475131)
21. Formula-based dosing for carboplatin.
Jodrell DI
Eur J Cancer; 1999 Sep; 35(9):1299-301. PubMed ID: 10658517
[No Abstract] [Full Text] [Related]
22. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
24. [The kidney in children under chemotherapy].
Cachat F; Guignard JP
Rev Med Suisse Romande; 1996 Dec; 116(12):985-93. PubMed ID: 9026889
[TBL] [Abstract][Full Text] [Related]
25. Melphalan combined with a carboplatin dose based on glomerular filtration rate followed by autologous stem cell rescue for children with solid tumours.
Shaw PJ; Pinkerton CR; Yaniv I
Bone Marrow Transplant; 1996 Dec; 18(6):1043-7. PubMed ID: 8971371
[TBL] [Abstract][Full Text] [Related]
26. Potential underdosing of carboplatin in gynecological malignancies.
de Lemos ML; Hamata L; Conklin J; Swenerton K
Gynecol Oncol; 2006 Sep; 102(3):599. PubMed ID: 16815537
[No Abstract] [Full Text] [Related]
27. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
Stöhr W; Paulides M; Bielack S; Jürgens H; Koscielniak E; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Feb; 48(2):140-7. PubMed ID: 16724313
[TBL] [Abstract][Full Text] [Related]
28. Weekly carboplatin as a strategy to prevent severe treatment-related emesis.
Markman M; Kulp B; Peterson G; Kennedy A
Gynecol Oncol; 2000 Aug; 78(2):265. PubMed ID: 10926818
[No Abstract] [Full Text] [Related]
29. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
30. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
[TBL] [Abstract][Full Text] [Related]
31. The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.
Markman M
Gynecol Oncol; 2007 Nov; 107(2):163-5. PubMed ID: 17675141
[No Abstract] [Full Text] [Related]
32. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
34. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
[TBL] [Abstract][Full Text] [Related]
35. Ischemic colitis associated with paclitaxel and carboplatin chemotherapy.
Tashiro M; Yoshikawa I; Kume K; Otsuki M
Am J Gastroenterol; 2003 Jan; 98(1):231-2. PubMed ID: 12526980
[No Abstract] [Full Text] [Related]
36. Drug allergy.
Honsinger RW
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):111. PubMed ID: 15328668
[No Abstract] [Full Text] [Related]
37. Comparative clinical pharmacology of cisplatin and carboplatin.
Murry DJ
Pharmacotherapy; 1997; 17(5 Pt 2):140S-145S. PubMed ID: 9322881
[TBL] [Abstract][Full Text] [Related]
38. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of the modified Jaffé method and an enzymatic method for the measurement of serum creatinine: practical consequences of a method change in the milieu of laboratory of oncologic clinical biology].
Jaudon T; Séronie-Vivien S; Chatelut é ; Chanut C; Favre G
Ann Biol Clin (Paris); 2000; 58(4):499-504. PubMed ID: 10932054
[No Abstract] [Full Text] [Related]
40. Reversal of dose-limiting carboplatin-induced peripheral neuropathy with TRPM8 activator, menthol, enables further effective chemotherapy delivery.
Storey DJ; Colvin LA; Mackean MJ; Mitchell R; Fleetwood-Walker SM; Fallon MT
J Pain Symptom Manage; 2010 Jun; 39(6):e2-4. PubMed ID: 20538177
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
